{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Oruka Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ORKA"},"Address":{"label":"Address","value":"11080 CIRCLEPOINT ROAD,SUITE 140, WESTMINSTER, Colorado, 80020, United States"},"Phone":{"label":"Phone","value":"+1 720 940-2200"},"Industry":{"label":"Industry","value":"Biotechnology: In Vitro & In Vivo Diagnostic Substances"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy."},"CompanyUrl":{"label":"Company Url","value":"https://www.arcabio.com"},"KeyExecutives":{"label":"Key Executives","value":[]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}